MLTX — MoonLake Immunotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $2.86bn
- $2.32bn
- 30
- 30
- 64
- 36
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | 10-K | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Net Income/Starting Line | -53.6 | -64.5 | -44.1 |
Depreciation | |||
Non-Cash Items | 14 | 10 | 7.51 |
Other Non-Cash Items | |||
Changes in Working Capital | 4.48 | -1.43 | -6.22 |
Change in Accounts Receivable | |||
Change in Prepaid Expenses | |||
Change in Other Assets | |||
Change in Accounts Payable | |||
Change in Accrued Expenses | |||
Cash from Operating Activities | -35.2 | -55.9 | -42.8 |
Capital Expenditures | -0.051 | -0.016 | -0.285 |
Purchase of Fixed Assets | |||
Other Investing Cash Flow Items | — | -32.3 | -24.9 |
Sale/Maturity of Investment | |||
Purchase of Investments | |||
Cash from Investing Activities | -0.051 | -32.3 | -25.2 |
Financing Cash Flow Items | — | 135 | -2.75 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Net Issuance / Retirement of Debt | |||
Cash from Financing Activities | 43.3 | 120 | 480 |
Foreign Exchange Effects | |||
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | 8.04 | 31.5 | 412 |